Materials Control of Nitric Oxide in Cancer Immunotherapy
- 14 November 2026
- journal article
- Published by Wiley in Advanced Materials
Abstract
Nitric oxide (NO) can suppress antitumor immunity, support tumor adaptation, or promote immune‐mediated killing, making its therapeutic manipulation highly dependent on exposure. This Review examines how materials control NO source, localization, release kinetics, and chemical fate in cancer immunotherapy, with particular attention to immune checkpoint blockade (ICB). We analyze polymeric donors, nanocarriers, injectable depots, and strategies for restricting endogenous NO production, linking their physicochemical properties to target exposure and immune function. Evidence from checkpoint‐treated models is distinguished from mechanisms established with other therapies and from human associations. Comparative analyses separate donor capacity from measured NO exposure, carrier accumulation from cellular delivery, and distant‐tumor control from demonstrated immune memory. Four overlapping endogenous contexts, comprising tumor adaptation, myeloid suppression, vascular dysfunction, and inflammatory effector activity, guide intervention design without constituting validated patient categories. We identify testable predictions concerning cellular selectivity, release kinetics, and spatial pharmacodynamic responses. Translation requires measurements that connect material behavior to a defined NO‐dependent process while demonstrating preservation of beneficial endothelial and immune functions. This framework provides a basis for evaluating when localized NO delivery or selective inhibition may support ICB, while recognizing the limits of current preclinical and clinical evidence.Funding Information
- National Natural Science Foundation of China (82272746)
This publication has 78 references indexed in Scilit:
- Gasotransmitter nitric oxide imaging in Alzheimer's disease and glioblastoma with diamino-cyclic-metalloiridium phosphorescence probesBiosensors and Bioelectronics, 2023
- Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapyCancer Cell, 2022
- KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burdenAnnals of Oncology, 2020
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 AntibodiesCancer Cell, 2018
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 TherapyCell, 2016
- L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor ActivityCell, 2016
- FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 AxisCancer Cell, 2015
- Subpopulations of myeloid‐derived suppressor cells impair T cell responses through independent nitric oxide‐related pathwaysInternational Journal of Cancer, 2013
- Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic ReprogrammingCancer Cell, 2012
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007